R. Brun del Re

Lack of action of prolactin suppression on the regulation of the human menstrual cycle

Bromocriptin (CB 154) has been found to suppress established lactation at a time when human plasma prolactin (HPRL) concentrations have already returned to the nonpregnant range. This action is due to inhibition of prolactin from the pituitary. It was then thought that a similar degree of inhibition induced during the menstrual cycle may help to uncover other possible biological actions of prolactin. In an attempt to elucidate this question eight breast-feeding mothers and seven normally menstruating volunteers underwent treatment with CB 154, including blood sampling during a sleep period. The dosage was 1 mg., three times daily, for 14 days in the first group and for a whole cycle in the normal volunteers. A control cycle preceded drug administration in the latter group. Prolactin (HPRL), growth hormone (HGH), luteotropin (LH), progesterone (PG), and estradiol (E2) were estimated (mean +/- standard error) along the menstrual cycles in the normal volunteers. HPRL and milk volumes were measured in the breast-feeding women in the base-line period and during treatment. In the postpartum group, basal HPRL had already reached normal levels prior to therapy (10.8 +/- 1.0 ng. per milliliter) and was significantly (p less than 0.002) depressed to 3.7 +/- 0.4 ng. per milliliter by CB 154. This degree of inhibition was effective in suppressing lactation within 24 to 48 hours in all of the subjects in that group. The fall in plasma HPRL from 9.5 +/- 1.5 ng. per milliliter to 3.2 +/- 0.2 ng. per milliliter observed in the normally menstruating women was similar to the one recorded in the breast-feeding group, but the sequence of hormonal changes during the menstrual cycle was not altered by treatment. The overnight study ensured around-the-clock prolactin inhibition. Results indicate no action of prolactin in the regulation of the human menstrual cycle at levels of inhibition at which a biological action of this hormone is clearly suppressed.

Lack of effect of methyl-ergonovine on postpartum lactation

There is little information about the action of ergot derivatives other than bromocriptine (CB 154) on plasma prolactin and milk secretion in human beings. In a recent report it has been suggested that ergonovine might interfere with lactation when administered post partum. The present study shows that methyl-ergonovine (Methergine), a closely related compound, has no action on prolactin or milk secretion as measured in a group of 10 breast feeding mothers in comparison with another 10 untreated puerperas.

PROLACTIN INHIBITION AND SUPPRESSION OF PUERPERAL LACTATION BY A BR-ERGOCRYPTINE (CB 154)

The antigalaclic action of Br-ergocryptine (CB 154 was studied in a group of women in the postpartum period who were compared with another two groups of normal breast-feeding mothers and estrogen-treated women. Treatment with Br-ergocryptine induced a fall in blood prolaclin concentrations to below the basal values found in nonlactaling women. No milk secretion was recorded in this group. This compound also inhibited the prolactin peak that normally occurs in response to suckling. Lactation suppression was also effective once it had been initiated, regardless of the prolactin concentrations at the time therapy was started. Inhibition of milk secretion by Brergocrypline also was observed in 2 women at a time when serum prolactin had reached normal levels and despite breast stimulation. Since treatment depressed serum prolactin values even further, it cannot be clearly explained whether the antigalaclic action was due simply to the fall in serum prolactin concentrations to a level below the normal range or to the abolition of the postsuction response. Exogenous administration of estrogen failed to inhibit prolactin secretion but was effective in suppressing lactation, thus suggesting a peripheral action on the mammary gland

Kinder- und Adoleszentengynäkologie / EDV

Ein 9jahriges Madchen wurde in die senologische Sprechstunde uberwiesen wegen einer seit 3 Monaten bestehenden Schwellung und lividen Verfarbung der linken Mamille, welche trotz lokaler antibiotischer, antimykotischer und Steroid-Therapie persistierte. Ipsilateral in der Axilla fanden sich einige vergroserte dolente Lymphknoten. Die genaue Anamneseerhebung ergab, das das Machen 4 Wochen vor Auftreten der Mamillenveranderung an der linken Mamma von einer Zecke gebissen wurde. Die Borrelien-Serologie ergab folgende Werte: IF-Abs-Test 5120 (normal bis 40), IF abs IgM 80, P39 EIA grenzwertig. Der Western-Blod auf Borrelia burgdorferi fiel im IgG- und IgM-Bereich positiv aus, wodurch eine Borreliose serologisch gesichert war. Histologisch konnte bei einer aus der linken Mamille entnommenen Probebiopsie die klinische Diagnose einer Lymphadenosis cutis benigna Bafverstedt nach Zeckenbis bestatigt werden. Unter systemischer antibotischer Therapie mit Fenoxypen 3x1 Mio/die wahrend 14 Tagen bildete sich die lokale Symptomatik deutlich zuruck.

Comparaison entre paramètres biochimiques (récepteurs hormonaux, protéine-kinase) et résultats thermographiques lors de cancers du sein

The prognosis of breast cancer is correlated with the histological grading, thermogenesis and some biochemical parameters of the tumor. In this study we looked for a possible correlation between therm